Cutter & CO Brokerage Inc. bought a new stake in Vivos Therapeutics, Inc. (NASDAQ:VVOS – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 38,100 shares of the company’s stock, valued at approximately $163,000. Cutter & CO Brokerage Inc. owned approximately 0.65% of Vivos Therapeutics as of its most recent SEC filing.
Analyst Upgrades and Downgrades
VVOS has been the subject of a number of analyst reports. Alliance Global Partners dropped their price objective on shares of Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 19th. Ascendiant Capital Markets reissued a “buy” rating and issued a $6.60 price target on shares of Vivos Therapeutics in a research note on Wednesday, November 20th.
View Our Latest Report on Vivos Therapeutics
Vivos Therapeutics Stock Up 3.0 %
About Vivos Therapeutics
Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.
Read More
- Five stocks we like better than Vivos Therapeutics
- Should You Invest in Penny Stocks?
- Buffett’s on the Sidelines – Should You Follow?
- How to Calculate Return on Investment (ROI)
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- 3 Warren Buffett Stocks to Buy Now
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.